The spectrum of benefit from checkpoint blockade in hypermutated tumors Research Letter
| Authors: | Rousseau, B.; Foote, M. B.; Maron, S. B.; Diplas, B. H.; Lu, S.; ArgileĢs, G.; Cercek, A.; Diaz, L. A. Jr |
| Title: | The spectrum of benefit from checkpoint blockade in hypermutated tumors |
| Keywords: | adolescent; adult; controlled study; aged; aged, 80 and over; middle aged; young adult; gene mutation; major clinical study; overall survival; genetics; mutation; mortality; advanced cancer; letter; neoplasm; neoplasms; colorectal cancer; phenotype; dna repair; melanoma; quality of life; cohort analysis; monoclonal antibody; neuroendocrine tumor; colorectal neoplasms; dna; kidney tumor; colorectal tumor; mismatch repair; dna mismatch repair; breast tumor; kaplan meier method; uvea melanoma; regression analysis; programmed death 1 ligand 1; programmed death 1 receptor; non small cell lung cancer; kaplan-meier estimate; mucosal melanoma; immune checkpoint inhibitor; antibodies, monoclonal, humanized; very elderly; humans; human; male; female; priority journal; pembrolizumab; programmed cell death 1 receptor; solid malignant neoplasm; immunological antineoplastic agent; antineoplastic agents, immunological |
| Journal Title: | New England Journal of Medicine |
| Volume: | 384 |
| Issue: | 12 |
| ISSN: | 0028-4793 |
| Publisher: | Massachusetts Medical Society |
| Date Published: | 2021-03-25 |
| Start Page: | 1168 |
| End Page: | 1170 |
| Language: | English |
| DOI: | 10.1056/NEJMc2031965 |
| PUBMED: | 33761214 |
| PROVIDER: | scopus |
| PMCID: | PMC8403269 |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 3 May 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
